Viral Hepatitis A, B and C in a Group of Transgender Women in Central Brazil
Transgender women (TGW) have limited access to affordable viral hepatitis testing, hepatitis B vaccination, and treatment. We aimed to estimate the prevalence of viral hepatitis A, B, and C, as well as to compare the adherence and immunogenicity of two hepatitis B vaccine schedules among TGW in Cent...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Tropical Medicine and Infectious Disease |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2414-6366/7/10/269 |
| _version_ | 1797469756555526144 |
|---|---|
| author | Lucila Pessuti Ferri Priscilla dos Santos Junqueira Mayara Maria Souza de Almeida Mariana Gomes Oliveira Brunna Rodrigues de Oliveira Bruno Vinícius Diniz e Silva Larissa Silva Magalhães Lívia Melo Villar Karlla Antonieta Amorim Caetano Márcia Maria Souza Megmar Aparecida dos Santos Carneiro Regina Maria Bringel Martins Sheila Araujo Teles |
| author_facet | Lucila Pessuti Ferri Priscilla dos Santos Junqueira Mayara Maria Souza de Almeida Mariana Gomes Oliveira Brunna Rodrigues de Oliveira Bruno Vinícius Diniz e Silva Larissa Silva Magalhães Lívia Melo Villar Karlla Antonieta Amorim Caetano Márcia Maria Souza Megmar Aparecida dos Santos Carneiro Regina Maria Bringel Martins Sheila Araujo Teles |
| author_sort | Lucila Pessuti Ferri |
| collection | DOAJ |
| description | Transgender women (TGW) have limited access to affordable viral hepatitis testing, hepatitis B vaccination, and treatment. We aimed to estimate the prevalence of viral hepatitis A, B, and C, as well as to compare the adherence and immunogenicity of two hepatitis B vaccine schedules among TGW in Central Brazil. A total of 440 TGW were interviewed and tested for hepatitis A, B, and C serological markers from 2017 to 2018. The hepatitis B vaccine was offered to 230 eligible TGW: 112 received a super accelerated hepatitis B vaccine schedule (G1) and 118 a standard schedule (G2). The antibody against the hepatitis A virus (HAV) was detected in 75.63% of the participants, and 12.3% of the TGW were exposed to the hepatitis B virus (HBV). Two (0.46%) participants were HBV carriers. Only 41.5% of the participants showed a serological profile of hepatitis B vaccination. The antibody against the hepatitis C virus (anti-HCV) was found in six participants (1.37%). Of the TGW who received the first vaccine dose, 62 (55.36%) and 49 (41.52%) in G1 and G2, respectively, received three doses (<i>p</i> = 0.036). The vaccine response was evaluated in 28 G1 and 22 G2 TGW; of these, 89.3% and 100% developed protective anti-hepatitis B surface-antigen titers, respectively (<i>p</i> = 0.113). Since one-third of younger transgender women are susceptible to HAV, hepatitis B immunization is low, and the anti-HCV rate is higher in this group than in the general population in Central Brazil, public-health attention is warranted. The super-accelerated scheme demonstrated better adhesion and good immunogenicity, suggesting that it would be a more cost-effective solution. |
| first_indexed | 2024-03-09T19:24:42Z |
| format | Article |
| id | doaj.art-39d9718e1ea044e3b1a9360c5dfcb87f |
| institution | Directory Open Access Journal |
| issn | 2414-6366 |
| language | English |
| last_indexed | 2024-03-09T19:24:42Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Tropical Medicine and Infectious Disease |
| spelling | doaj.art-39d9718e1ea044e3b1a9360c5dfcb87f2023-11-24T03:00:05ZengMDPI AGTropical Medicine and Infectious Disease2414-63662022-09-0171026910.3390/tropicalmed7100269Viral Hepatitis A, B and C in a Group of Transgender Women in Central BrazilLucila Pessuti Ferri0Priscilla dos Santos Junqueira1Mayara Maria Souza de Almeida2Mariana Gomes Oliveira3Brunna Rodrigues de Oliveira4Bruno Vinícius Diniz e Silva5Larissa Silva Magalhães6Lívia Melo Villar7Karlla Antonieta Amorim Caetano8Márcia Maria Souza9Megmar Aparecida dos Santos Carneiro10Regina Maria Bringel Martins11Sheila Araujo Teles12Faculty of Nursing, Federal University of Goiás, Goiânia 74690-900, BrazilFaculty of Nursing, Federal University of Goiás, Goiânia 74690-900, BrazilFaculty of Nursing, Federal University of Goiás, Goiânia 74690-900, BrazilFaculty of Nursing, Federal University of Goiás, Goiânia 74690-900, BrazilInstitute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74690-900, BrazilInstitute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74690-900, BrazilFaculty of Nursing, Federal University of Goiás, Goiânia 74690-900, BrazilLaboratory of Viral Hepatitis, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro 21040-900, BrazilFaculty of Nursing, Federal University of Goiás, Goiânia 74690-900, BrazilFaculty of Nursing, Federal University of Goiás, Goiânia 74690-900, BrazilInstitute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74690-900, BrazilInstitute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74690-900, BrazilFaculty of Nursing, Federal University of Goiás, Goiânia 74690-900, BrazilTransgender women (TGW) have limited access to affordable viral hepatitis testing, hepatitis B vaccination, and treatment. We aimed to estimate the prevalence of viral hepatitis A, B, and C, as well as to compare the adherence and immunogenicity of two hepatitis B vaccine schedules among TGW in Central Brazil. A total of 440 TGW were interviewed and tested for hepatitis A, B, and C serological markers from 2017 to 2018. The hepatitis B vaccine was offered to 230 eligible TGW: 112 received a super accelerated hepatitis B vaccine schedule (G1) and 118 a standard schedule (G2). The antibody against the hepatitis A virus (HAV) was detected in 75.63% of the participants, and 12.3% of the TGW were exposed to the hepatitis B virus (HBV). Two (0.46%) participants were HBV carriers. Only 41.5% of the participants showed a serological profile of hepatitis B vaccination. The antibody against the hepatitis C virus (anti-HCV) was found in six participants (1.37%). Of the TGW who received the first vaccine dose, 62 (55.36%) and 49 (41.52%) in G1 and G2, respectively, received three doses (<i>p</i> = 0.036). The vaccine response was evaluated in 28 G1 and 22 G2 TGW; of these, 89.3% and 100% developed protective anti-hepatitis B surface-antigen titers, respectively (<i>p</i> = 0.113). Since one-third of younger transgender women are susceptible to HAV, hepatitis B immunization is low, and the anti-HCV rate is higher in this group than in the general population in Central Brazil, public-health attention is warranted. The super-accelerated scheme demonstrated better adhesion and good immunogenicity, suggesting that it would be a more cost-effective solution.https://www.mdpi.com/2414-6366/7/10/269hepatitis Ahepatitis Bhepatitis Cimmunogenicitytransgender womenvaccination |
| spellingShingle | Lucila Pessuti Ferri Priscilla dos Santos Junqueira Mayara Maria Souza de Almeida Mariana Gomes Oliveira Brunna Rodrigues de Oliveira Bruno Vinícius Diniz e Silva Larissa Silva Magalhães Lívia Melo Villar Karlla Antonieta Amorim Caetano Márcia Maria Souza Megmar Aparecida dos Santos Carneiro Regina Maria Bringel Martins Sheila Araujo Teles Viral Hepatitis A, B and C in a Group of Transgender Women in Central Brazil Tropical Medicine and Infectious Disease hepatitis A hepatitis B hepatitis C immunogenicity transgender women vaccination |
| title | Viral Hepatitis A, B and C in a Group of Transgender Women in Central Brazil |
| title_full | Viral Hepatitis A, B and C in a Group of Transgender Women in Central Brazil |
| title_fullStr | Viral Hepatitis A, B and C in a Group of Transgender Women in Central Brazil |
| title_full_unstemmed | Viral Hepatitis A, B and C in a Group of Transgender Women in Central Brazil |
| title_short | Viral Hepatitis A, B and C in a Group of Transgender Women in Central Brazil |
| title_sort | viral hepatitis a b and c in a group of transgender women in central brazil |
| topic | hepatitis A hepatitis B hepatitis C immunogenicity transgender women vaccination |
| url | https://www.mdpi.com/2414-6366/7/10/269 |
| work_keys_str_mv | AT lucilapessutiferri viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT priscilladossantosjunqueira viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT mayaramariasouzadealmeida viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT marianagomesoliveira viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT brunnarodriguesdeoliveira viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT brunoviniciusdinizesilva viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT larissasilvamagalhaes viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT liviamelovillar viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT karllaantonietaamorimcaetano viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT marciamariasouza viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT megmaraparecidadossantoscarneiro viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT reginamariabringelmartins viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil AT sheilaaraujoteles viralhepatitisabandcinagroupoftransgenderwomenincentralbrazil |